FOXO4-DRI
A senolytic peptide designed to selectively clear senescent cells by disrupting the FOXO4-p53 interaction, studied for anti-aging applications.
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
What is FOXO4-DRI?
FOXO4-DRI is a modified peptide designed to target and eliminate senescent cells — aged cells that no longer divide but release inflammatory signals that damage surrounding tissue. By disrupting the interaction between FOXO4 and p53 proteins, it may trigger senescent cells to undergo programmed cell death (apoptosis) while leaving healthy cells unaffected.
Why People Talk About It
Clearance of senescent cells
PreliminaryReversal of age-related tissue decline
PreliminaryImproved physical function in aging
LimitedReduced chronic inflammation
PreliminaryHow It Works
FOXO4-DRI works by blocking a protective signal that keeps damaged old cells alive. When this signal is disrupted, the body's natural cleanup processes can remove these harmful cells, potentially reducing inflammation and improving tissue function.
Common Questions
Safety Information
Common Side Effects
Cautions
- • Very limited human data
- • Not FDA-approved
- • Complex mechanism requires expert guidance
- • Potential for unintended cell death
What We Don't Know
Nearly all data comes from animal models. Human safety, dosing, and long-term effects are essentially unknown.
Published Research
6 studiesThe disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway
FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
Research Insights
Related Peptides
Epithalon
PreliminaryA synthetic tetrapeptide studied for its potential to activate telomerase and influence cellular aging.
SS-31
EmergingA mitochondria-targeted peptide in clinical trials for heart failure and mitochondrial diseases.
MOTS-c
EmergingA mitochondria-derived peptide that regulates metabolic homeostasis and has been called an 'exercise mimetic.'
Quick Facts
- Class
- Senolytic Peptide
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Feb 2026
- Citations
- 6PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.
Interested in this peptide? A Noho clinician can help determine if it's right for you.
Talk to a Clinician